Cloning

Top Cybersecurity Professionals to Cover AI and the Human Layer at KB4-CON 2024

Retrieved on: 
Wednesday, January 31, 2024

TAMPA BAY, Fla., Jan. 31, 2024 /PRNewswire/ -- KnowBe4, the provider of the world's largest security awareness training and simulated phishing platform, today announced registration details and its lineup of speakers who will cover the latest topics of cybersecurity with a focus on Securing the Future: AI and the Human Layer at the organization's annual user conference KB4-CON 2024 in Orlando, FL March 4-6.

Key Points: 
  • Registration for the annual event is open for KnowBe4 customers, partners and guests at a nominal registration fee.
  • Attendance is limited and so early registration is encouraged as last year's event was a sell-out.
  • KB4-CON 2024 will be open to all security professionals from March 4-6, 2024.
  • The event sessions will focus on peer insights, product updates and best practices, as well as some of the hottest topics in cybersecurity such as AI, ransomware, security awareness and more.

Vidnoz AI Unveils Voice Clone to Enhance Brand Attributes and User Engagement

Retrieved on: 
Wednesday, January 17, 2024

With ultra-realistic Voice Clone and Custom Avatar, Vidnoz empowers brands to create exclusive and recognizable video content that resonates directly with the audience, enhancing brand affinity, loyalty, and user engagement.

Key Points: 
  • With ultra-realistic Voice Clone and Custom Avatar, Vidnoz empowers brands to create exclusive and recognizable video content that resonates directly with the audience, enhancing brand affinity, loyalty, and user engagement.
  • Vidnoz AI, recognizing the importance of personalization, provides free access for users to clone their unique voice, and an advanced way to custom their exclusive avatar.
  • Additionally, Vidnoz AI has launched a series of free new AI Tools, Vidnoz AI Voice Changer, Vidnoz AI Cartoon Generator, and AI Text to Video, AI Dancing Photo.
  • Sam Brown, Product Manager of Vidnoz AI, states: "Voice Cloning is a game changer, taking AI videos to a brand new level.

Emerging ethical issues highlighted related to the use of Artificial Intelligence in U.S. legal system

Retrieved on: 
Wednesday, November 15, 2023

Reston, Va., Nov. 15, 2023 (GLOBE NEWSWIRE) -- In an unprecedented move, the National Court Reporters Association (NCRA), the country’s leading organization representing stenographic court reporters, captioners, and legal videographers, has published its first white paper highlighting the emerging ethical issues related to the implementation of artificial intelligence in the U. S. judicial system.

Key Points: 
  • Reston, Va., Nov. 15, 2023 (GLOBE NEWSWIRE) -- In an unprecedented move, the National Court Reporters Association (NCRA), the country’s leading organization representing stenographic court reporters, captioners, and legal videographers, has published its first white paper highlighting the emerging ethical issues related to the implementation of artificial intelligence in the U. S. judicial system.
  • “Raising the alarm of the emerging threat of artificial intelligence to nation’s judiciary starts with this white paper,” NCRA Executive Director Dave Wenhold, CAE, PLC, added.
  • “The judicial system, and society as a whole, depends heavily on the services that only a qualified, NCRA certified stenographic court reporter can provide,” Wenhold said.
  • “By making this document public facing, NCRA is taking that bold step into advocating for our legal system to remain free from foreign interference and in turn, a secure democracy.”
    View the NCRA white paper and the executive summary “Emerging Ethical and Legal Issues Related to the Use of Artificial Intelligence (AI), Automatic Speech Recognition (ASR), Voice Cloning, and Digital Audio Recording of Legal Proceedings” here .

Medical Segment Dominates, Expected to Reach $70.4 Billion by 2030 in the Global Recombinant DNA Technology Market

Retrieved on: 
Wednesday, November 1, 2023

DUBLIN, Oct. 31, 2023 /PRNewswire/ -- The "Recombinant DNA Technology: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Oct. 31, 2023 /PRNewswire/ -- The "Recombinant DNA Technology: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
  • The global market for Recombinant DNA Technology estimated at US$64.7 Billion in the year 2022, is projected to reach a revised size of US$93.7 Billion by 2030, growing at a CAGR of 4.7% over the analysis period 2022-2030.
  • Medical, one of the segments analyzed in the report, is projected to record 5.2% CAGR and reach US$70.4 Billion by the end of the analysis period.
  • The U.S. Market is Estimated at $18.9 Billion, While China is Forecast to Grow at 4.4% CAGR
    The Recombinant DNA Technology market in the U.S. is estimated at US$18.9 Billion in the year 2022.

FineShare Singify: Ignite Your Music Creation with the Next Level of AI Song Cover!

Retrieved on: 
Thursday, August 24, 2023

This month, FineShare is proud to introduce FineShare Singify , an innovative and free AI song cover generator that aims to redefine music creation and provide an unprecedented carnival for music lovers.

Key Points: 
  • This month, FineShare is proud to introduce FineShare Singify , an innovative and free AI song cover generator that aims to redefine music creation and provide an unprecedented carnival for music lovers.
  • Jared Dun, CEO and co-founder of FineShare said: "FineShare Singify's launch marks our continuous innovation in the AI Voice field.
  • FineShare Singify provides multiple simple and convenient ways of making AI song covers:
    Song search: Find any song within the app and create song covers with one click, no threshold for creation.
  • Unique to FineShare Singify is the free AI song cover feature, which makes music creation accessible to everyone.

Arcserve Boosts Economics and ROI of Cloud Services for MSPS

Retrieved on: 
Tuesday, August 24, 2021

Arcserve, the world's most experienced data, and ransomware protection provider, today announced it has enhanced StorageCraft Cloud Services Basic so that MSPs can offer best-in-class cloud backup and disaster recovery services to a broader range of customers with unprecedented ROI and profit potential.

Key Points: 
  • Arcserve, the world's most experienced data, and ransomware protection provider, today announced it has enhanced StorageCraft Cloud Services Basic so that MSPs can offer best-in-class cloud backup and disaster recovery services to a broader range of customers with unprecedented ROI and profit potential.
  • With StorageCraft Cloud Services Basic, MSPs can service a wider range of customer use cases, including small businesses and data protection for small physical and virtual workstations.
  • Unlike typical cloud services providers that add fees for features such as bringing customer data in and out of the cloud or recovering files in the event of failure, these features are standard in StorageCraft Cloud Services.
  • Enhancing the economics and ROI of StorageCraft Cloud Services does this.

Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August

Retrieved on: 
Tuesday, August 3, 2021

Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in the following August investor conferences:

Key Points: 
  • Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that the company will participate in the following August investor conferences:
    2021 Wedbush PacGrow Healthcare Virtual Conference, panel: So Let it Be (Re)Written - Updates in Gene Modulation at 9:10 a.m.
  • ET on Tuesday, August 10
    Magenta Therapeutics is a clinical-stage biotechnology company developing medicines designed to bring the curative power of stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases.
  • Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.
  • Magenta is based in Cambridge, Mass.

Cellino Appoints Industry Pioneer Robert J. Palay to the Board

Retrieved on: 
Tuesday, August 3, 2021

Cellino , a personalized regenerative medicine company developing an AI-guided laser editing platform for autologous cell-based therapies, today announced the appointment of industry pioneer Robert J. Palay, J.D., M.B.A., to the Cellino Board of Directors.

Key Points: 
  • Cellino , a personalized regenerative medicine company developing an AI-guided laser editing platform for autologous cell-based therapies, today announced the appointment of industry pioneer Robert J. Palay, J.D., M.B.A., to the Cellino Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20210803005032/en/
    Mr. Palay is one of the pioneers of the induced pluripotent stem cell (iPSC) industry.
  • "We are pleased to welcome Robert to the Cellino Board," said Nabiha Saklayen, Ph.D, CEO & Co-Founder, Cellino.
  • "I am thrilled to join the Cellino Board," said Robert J. Palay.

FDA Gives Green Light for Multiple Sclerosis Stem Cell Trial

Retrieved on: 
Tuesday, July 27, 2021

Non-profit research organization Hope Biosciences Stem Cell Research Foundation (HBSCRF) has received FDA authorization for a randomized, double-blind, single center, Phase II clinical trial to assess the efficacy of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells in improving symptoms and quality of life in patients with mild-to-moderate multiple sclerosis (MS).

Key Points: 
  • Non-profit research organization Hope Biosciences Stem Cell Research Foundation (HBSCRF) has received FDA authorization for a randomized, double-blind, single center, Phase II clinical trial to assess the efficacy of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells in improving symptoms and quality of life in patients with mild-to-moderate multiple sclerosis (MS).
  • A single infusion in the treatment group consists of 200 million stem cells, or approximately 1.2 billion stem cells per patient over the course of study.
  • HBSCRF remains the only organization globally to administer pure, fresh mesenchymal stem cells, an adult stem cell harvested from fat, in such high quantities over repeat treatments.
  • Clinical trial authorizations encompass COVID-19 prevention and treatment , traumatic brain injury , Parkinsons disease , and multiple sclerosis.

InGeneron Reports First-In-Human Microscopic Evidence of Adult Tendon Regeneration Following Autologous Stem Cell Treatment

Retrieved on: 
Monday, July 26, 2021

This newly-released research paper, titled First Immunohistochemical Evidence of Human Tendon Repair Following Stem Cell Injection: A Case Report and Review of Literature , was published in the World Journal of Stem Cells on July 23, 2021 (DOI: https://dx.doi.org/10.4252/wjsc.v13.i7.944 ).

Key Points: 
  • This newly-released research paper, titled First Immunohistochemical Evidence of Human Tendon Repair Following Stem Cell Injection: A Case Report and Review of Literature , was published in the World Journal of Stem Cells on July 23, 2021 (DOI: https://dx.doi.org/10.4252/wjsc.v13.i7.944 ).
  • The analysis strongly indicates regenerative healing of the tendon, resulting from transformation of UA-ADRCs into new tendon tissue.
  • Importantly, the investigated tendon showed evidence of histological regeneration without scar formation, a finding indicating significant advantages over existing treatments options.
  • The microscopic images of the tendon treated with stem cells clearly demonstrate that a different type of healing had taken place.